A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-02

Study Completion Date

2024-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

NCT04084366

Locally Advanced Solid Tumor

TERMINATED PHASE1/PHASE2

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

NCT07124117

Advanced Solid Tumor

RECRUITING PHASE1/PHASE2

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

NCT01529684

Advanced Solid Tumors Pharmacokinetics of 14C-OSI-906

COMPLETED PHASE1

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

NCT06480240

Advanced Solid Tumor

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Phase 1 Trial of Oral Ixabepilone

NCT00632424

Advanced Solid Tumors

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Pancreatic Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose escalation phase

OBI-3424 (1.0 mg/m\^2 to 14.0 mg/m\^2) will be administered by IV infusion on Days 1 and 8 of each 21-day cycle or Day 1 of each 21-day cycle to determine the MTD and RP2D with a classic 3+3 dose escalation design.

Group Type EXPERIMENTAL

OBI-3424

Intervention Type DRUG

liquid formulation for Intravenous infusion

Cohort expansion phase

OBI-3424 (12 mg/m\^2) will be administered by IV infusion on Day 1 of each 21-day cycle.

Group Type EXPERIMENTAL

OBI-3424

Intervention Type DRUG

liquid formulation for Intravenous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OBI-3424

liquid formulation for Intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. At least 18 years of age
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
3. Recovered from toxicities of prior therapy to Grade 0 or 1
4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
6. Acceptable liver function:

1. Bilirubin ≤1.5 × institutional ULN
2. AST and ALT ≤3.0 × ULN, or ≤5.0 × ULN for subjects with liver involvement
7. Acceptable renal function:

a. Creatinine clearance \>30 mL/min according to the Cockcroft-Gault formula
8. Acceptable hematologic status (without hematologic support, other than red blood cell transfusion):

1. ANC ≥1500 cells/μL
2. Platelet count ≥100,000/μL
3. Hemoglobin ≥9.0 g/dL (prior packed red blood cell transfusion or erythropoietin support is allowed).
9. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method \[such as condom plus diaphragm with spermicide\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation.

10. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
11. Tumor progression after most recent therapy

12. Available tumor tissue, either archival or fresh (fresh preferred).
13. For treatment, an AKR1C3 IHC H-score of ≥ 100 using a validated IHC assay in one of the following tumor types to be enrolled in the respective cohort:

1. Cohort A: Pancreatic Adenocarcinoma
2. Cohort B: Basket (any solid tumor type other than pancreatic adenocarcinoma)

Exclusion Criteria

1. Prior radiotherapy to more than 25% of the bone marrow
2. Symptomatic brain metastases, unless previously treated and well controlled for at least 4 weeks after central nervous system (CNS)-directed treatment as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the Screening Period. Patients with known leptomeningeal disease are excluded.
3. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the current study
4. Patients with hepatocellular carcinoma (applies to Expansion Phase only)
5. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
6. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
7. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)
8. Concomitant use of strong CYP3A4 inhibitors/inducers
9. Concomitant use of naproxen within a 48-hour window before and after OBI-3424 dosing
10. Females who are pregnant or breast-feeding
11. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
12. Unwillingness or inability to comply with the study protocol for any reason

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No